{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:20:02Z","timestamp":1773098402348,"version":"3.50.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"941","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of arachidonic acid to the potent platelet agonist thromboxane A2 but does not prevent platelet activation occurring via various signalling pathways that are independent of thromboxane A2 release. Therefore a number of other compounds have been developed to complement aspirin\u2019s beneficial effect. These include the thienopyridines (clopidogrel and ticlopidine), dipyridamole, and the \u03b1IIb\u03b23 (glycoprotein IIb\/IIIa) receptor inhibitors.<\/jats:p>","DOI":"10.1136\/pgmj.2003.007062","type":"journal-article","created":{"date-parts":[[2004,3,11]],"date-time":"2004-03-11T22:33:33Z","timestamp":1079044413000},"page":"155-164","source":"Crossref","is-referenced-by-count":40,"title":["Antiplatelet therapy in cardiovascular disease"],"prefix":"10.1093","volume":"80","author":[{"given":"M W H","family":"Behan","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, University Hospital , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R F","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Group, Northern General Hospital , Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,3,11]]},"reference":[{"key":"2023050810105862900_R1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/oxfordjournals.eurheartj.a015434","article-title":"The burden of cardiovascular diseases on mortality in Europe: Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe.","volume":"18","author":"Sans","year":"1997","journal-title":"Eur Heart J"},{"key":"2023050810105862900_R2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes.","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"key":"2023050810105862900_R3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis as an inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00045391-200111000-00009","article-title":"How to get from antiplatelet to antithrombotic treatment.","volume":"8","author":"Eisert","year":"2001","journal-title":"Am J Ther"},{"key":"2023050810105862900_R5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation.","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl","key":"2023050810105862900_R6","first-page":"S27","article-title":"The importance of platelet aggregation in coronary artery disease.","volume":"7","author":"Heptinstall","year":"2000","journal-title":"British Journal of Cardiology"},{"key":"2023050810105862900_R7","first-page":"1184","article-title":"Acute myocardial infarction","volume-title":"Heart disease: a textbook of cardiovascular medicine","author":"Antman","year":"1997"},{"key":"2023050810105862900_R8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes.","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/0735-1097(94)90657-2","article-title":"Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.","volume":"23","author":"Fernandez-Ortiz","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2023050810105862900_R10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption.","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"2023050810105862900_R11","article-title":"Pathophysiology and clinical recognition","volume-title":"Cardiovascular medicine","author":"Willerson","year":"1995"},{"key":"2023050810105862900_R12","first-page":"149","article-title":"Platelet activation: signal transduction via membrane receptors.","volume":"74","author":"Clemetson","year":"1995","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-0038-1649570","article-title":"The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.","volume":"70","author":"Robbie","year":"1993","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R14","first-page":"413","article-title":"Attenuation of thrombolysis by release of plasminogen activator type-1 from platelets.","volume":"72","author":"Torr-Brown","year":"1993","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R15","first-page":"415","article-title":"Aspirin\u2014the novel antiplatelet drug.","volume":"4","author":"Pawar","year":"1998","journal-title":"Hong Kong Medical Journal"},{"key":"2023050810105862900_R16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archotol.1945.00680040033004","article-title":"Acetyl salicylic acid, probable cause for secondary, post tonsillectomy haemorrhage. Preliminary report.","volume":"42","author":"Singer","year":"1945","journal-title":"Arch Otolaryngol"},{"key":"2023050810105862900_R17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug.","volume":"330","author":"Patrano","year":"1994","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2023050810105862900_R19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0002-8703(95)90353-4","article-title":"Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses.","volume":"130","author":"Buerke","year":"1995","journal-title":"Am Heart J"},{"key":"2023050810105862900_R20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Society.","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulphinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R22","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina.","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0735-1097(91)90489-V","article-title":"Aspirin (75 mg\/day) after an episode of unstable coronary artery disease: long-term effects on the risk of myocardial infarction, occurrence of severe angina and the need for revascularisation.","volume":"18","author":"Research Group on Instability in Coronary Artery Disease in Southeast Sweden (RISC)","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"2023050810105862900_R24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/0002-9343(90)90220-8","article-title":"Aspirin in the primary prevention of angina pectoris in a randomised trial of United States physicians.","volume":"89","author":"Manson","year":"1990","journal-title":"Am J Med"},{"key":"2023050810105862900_R25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.7326\/0003-4819-114-10-835","article-title":"Low-dose aspirin therapy for chronic stable angina: a randomised placebo controlled trial.","volume":"114","author":"Ridker","year":"1991","journal-title":"Ann Intern Med"},{"key":"2023050810105862900_R26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients in patients with stable chronic angina pectoris.","volume":"340","author":"Juul-Moller","year":"1992","journal-title":"Lancet"},{"key":"2023050810105862900_R27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.77.1.142","article-title":"Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.","volume":"77","author":"Fitzgerald","year":"1988","journal-title":"Circulation"},{"key":"2023050810105862900_R28","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.","volume":"ii","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"2023050810105862900_R29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1993.tb05689.x","article-title":"The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.","volume":"35","author":"Roderick","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"2023050810105862900_R30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long-term use of aspirin: met-analysis.","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"2023050810105862900_R31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/09537109876799","article-title":"Clopidogrel: a review of its mechanism of action.","volume":"9","author":"Savi","year":"1998","journal-title":"Platelets"},{"key":"2023050810105862900_R32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00002512-199608030-00006","article-title":"Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.","volume":"8","author":"Noble","year":"1996","journal-title":"Drugs Aging"},{"key":"2023050810105862900_R33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2023050810105862900_R34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.","volume":"334","author":"Scheming","year":"1996","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"2023050810105862900_R36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"CURE Study Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"2023050810105862900_R38","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention.","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"2023050810105862900_R39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/0953710021000024402","article-title":"Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.","volume":"13","author":"Storey","year":"2002","journal-title":"Platelets"},{"key":"2023050810105862900_R40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1055\/s-0037-1613242","article-title":"Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.","volume":"88","author":"Storey","year":"2002","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R41","first-page":"V85","article-title":"The persantin-aspirin reinfarction study.","volume":"62","author":"Persantin-Aspirin Reinfarction Study (PARIS) Research Group","year":"1980","journal-title":"Circulation"},{"key":"2023050810105862900_R42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study 2.","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"2023050810105862900_R43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1642668","article-title":"Function and regulation of the B3 integrins in haemostasis and vascular biology.","volume":"74","author":"Shattil","year":"1995","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0038-1642662","article-title":"Platelet activation: signal transduction via membrane receptors.","volume":"74","author":"Clemetson","year":"1995","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0037-1616241","article-title":"Anti-GPIIb\/IIIa drugs: current strategies and future directions.","volume":"86","author":"Coller","year":"2001","journal-title":"Thromb Haemost"},{"key":"2023050810105862900_R46","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/S0735-1097(00)00979-7","article-title":"A critical appraisal of platelet glycoprotein IIb\/IIIa inhibition.","volume":"36","author":"Chew","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023050810105862900_R47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0002-8703(99)70075-X","article-title":"Development of eptifibatide.","volume":"138","author":"Scarborough","year":"1999","journal-title":"Am Heart J"},{"key":"2023050810105862900_R48","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty.","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R49","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation.","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study.","volume":"349","author":"CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"2023050810105862900_R51","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"For the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial.","volume":"354","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"2023050810105862900_R52","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II.","volume":"349","author":"IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"2023050810105862900_R53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.287.5.618","article-title":"Long-term efficacy of platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention.","volume":"287","author":"O\u2019Shea","year":"2002","journal-title":"JAMA"},{"key":"2023050810105862900_R54","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischaemic events with percutaneous coronary revascularization.","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00392-003-0895-6","article-title":"Pharmacodynamic and clinical trials of glycoprotein IIb\/IIIa inhibitors and potential relationship of results to dosing.","volume":"92","author":"Hobbach","year":"2003","journal-title":"Z Kardiol"},{"key":"2023050810105862900_R56","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischaemic Syndrome Management Study Investigators.","volume":"338","author":"PRISM Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R57","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.","volume":"338","author":"Platelet Receptor in Ischaemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes.","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R59","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina.","volume":"97","author":"PARAGON Investigators","year":"1998","journal-title":"Circulation"},{"key":"2023050810105862900_R60","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.","volume":"357","author":"GUSTO IV-ACS Investigators","year":"2001","journal-title":"Lancet"},{"key":"2023050810105862900_R61","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"The TACTICS- Thrombolysis in Myocardial Infarction. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban.","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R62","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"For the ADMIRAL Investigators. Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction.","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT).","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"key":"2023050810105862900_R64","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"For the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"2023050810105862900_R65","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.99.21.2720","article-title":"Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI 14) trial. The TIMI 14 Investigators.","volume":"99","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"2023050810105862900_R66","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial.","volume":"357","author":"GUSTO V Investigators","year":"2001","journal-title":"Lancet"},{"key":"2023050810105862900_R67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orofiban in patients with unstable coronary syndromes (OPUS-TIMI 16).","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"2023050810105862900_R68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischaemic heart events post-acute coronary syndromes.","volume":"355","author":"SYMPHONY Investigators","year":"2000","journal-title":"Lancet"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/80\/941\/155\/50224403\/postgradmedj-80-155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/80\/941\/155\/50224403\/postgradmedj-80-155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:13:09Z","timestamp":1683540789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/80\/941\/155\/7033852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":68,"journal-issue":{"issue":"941","published-online":{"date-parts":[[2004,3,11]]},"published-print":{"date-parts":[[2004,3,11]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2003.007062","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,3]]},"published":{"date-parts":[[2004,3]]}}}